ISPECIMEN INC (ISPC) Stock Price, Forecast & Analysis

NASDAQ:ISPC • US45032V2079

0.303 USD
-0.02 (-4.84%)
At close: Feb 13, 2026
0.313 USD
+0.01 (+3.3%)
After Hours: 2/13/2026, 8:18:02 PM

ISPC Key Statistics, Chart & Performance

Key Statistics
Market Cap2.96M
Revenue(TTM)3.35M
Net Income(TTM)-11.53M
Shares9.77M
Float9.70M
52 Week High3.18
52 Week Low0.26
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-6.95
PEN/A
Fwd PEN/A
Earnings (Next)N/A
IPO2021-06-17
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Technology
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Technology
ISPC short term performance overview.The bars show the price performance of ISPC in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60

ISPC long term performance overview.The bars show the price performance of ISPC in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of ISPC is 0.303 USD. In the past month the price decreased by -27.86%. In the past year, price decreased by -83.71%.

ISPECIMEN INC / ISPC Daily stock chart

ISPC Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating
ISPC Full Technical Analysis Report

ISPC Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to ISPC. The financial health of ISPC is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ISPC Full Fundamental Analysis Report

ISPC Financial Highlights

Over the last trailing twelve months ISPC reported a non-GAAP Earnings per Share(EPS) of -6.95. The EPS increased by 63.29% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -128.18%
ROE -375.34%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%77.27%
Sales Q2Q%-95.99%
EPS 1Y (TTM)63.29%
Revenue 1Y (TTM)-67.73%
ISPC financials

ISPC Forecast & Estimates

For the next year, analysts expect an EPS growth of 10.23% and a revenue growth 11.76% for ISPC


Analysts
Analysts82.86
Price TargetN/A
EPS Next Y10.23%
Revenue Next Year11.76%
ISPC Analyst EstimatesISPC Analyst Ratings

ISPC Ownership

Ownership
Inst Owners3.51%
Ins Owners0.26%
Short Float %3.21%
Short Ratio0.23
ISPC Ownership

ISPC Latest News, Press Relases and Analysis

All ISPC news

ISPC Competitors/Peers

The largest stocks on the US markets in the "Health Care Technology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
VEEV VEEVA SYSTEMS INC-CLASS A19.8828.272B
DOCS DOXIMITY INC-CLASS A14.294.564B
WAY WAYSTAR HOLDING CORP13.574.159B
HTFL HEARTFLOW INC N/A1.915B
CCLDO CARECLOUD INC - CCLD 8 3/4 PERP231.731.099B
LFMDP LIFEMD INC - LFMD 8 7/8 PERP N/A1.078B
CERT CERTARA INC11.921.062B
SDGR SCHRODINGER INC N/A833.095M
TDOC TELADOC HEALTH INC N/A792.754M
GDRX GOODRX HOLDINGS INC-CLASS A4.94739.957M

About ISPC

Company Profile

ISPC logo image iSpecimen, Inc. is a healthcare organization that engages in procurement of human biospecimen. The company is headquartered in Woburn, Massachusetts and currently employs 24 full-time employees. The company went IPO on 2021-06-17. The firm addresses a critical challenge, which focuses on connecting life science researchers who need human biofluids, tissues, and living cells (biospecimens) for their research. The Company’s iSpecimen Marketplace platform is designed to solve this problem and transform the biospecimen procurement process to accelerate medical discovery. Its technology consolidates the biospecimen buying experience in a single, online marketplace that brings together healthcare providers who have biospecimens and researchers across industry, academia, and government institutions who need them. In addition to providing the technology platform to connect researchers and healthcare providers, the Company handles all marketing, sales, contracting, and compliance functions across both sides of the marketplace. The iSpecimen Marketplace technology comprises four functional areas: search, workflow, data and administrative, compliance and reporting.

Company Info

ISPECIMEN INC

8 Cabot Road, Suite 1800

Woburn MASSACHUSETTS US

CEO: Christopher Ianelli

Employees: 24

ISPC Company Website

ISPC Investor Relations

Phone: 17813016700

ISPECIMEN INC / ISPC FAQ

What does ISPECIMEN INC do?

iSpecimen, Inc. is a healthcare organization that engages in procurement of human biospecimen. The company is headquartered in Woburn, Massachusetts and currently employs 24 full-time employees. The company went IPO on 2021-06-17. The firm addresses a critical challenge, which focuses on connecting life science researchers who need human biofluids, tissues, and living cells (biospecimens) for their research. The Company’s iSpecimen Marketplace platform is designed to solve this problem and transform the biospecimen procurement process to accelerate medical discovery. Its technology consolidates the biospecimen buying experience in a single, online marketplace that brings together healthcare providers who have biospecimens and researchers across industry, academia, and government institutions who need them. In addition to providing the technology platform to connect researchers and healthcare providers, the Company handles all marketing, sales, contracting, and compliance functions across both sides of the marketplace. The iSpecimen Marketplace technology comprises four functional areas: search, workflow, data and administrative, compliance and reporting.


What is the current price of ISPC stock?

The current stock price of ISPC is 0.303 USD. The price decreased by -4.84% in the last trading session.


Does ISPC stock pay dividends?

ISPC does not pay a dividend.


How is the ChartMill rating for ISPECIMEN INC?

ISPC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


On which exchange is ISPC stock listed?

ISPC stock is listed on the Nasdaq exchange.


Can you provide the PE ratio for ISPC stock?

ISPECIMEN INC (ISPC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.95).